TD Cowen Reiterates Buy Rating on HCA Healthcare
TD Cowen maintains its buy rating on HCA Healthcare with a $431 price target, a 11.63% upside from the current price.
Key Points
- TD Cowen reiterated its buy rating for HCA Healthcare, setting a price target of $431 on June 22, 2026.
- TD Cowen's $431 price target implies 11.63% upside from HCA Healthcare, Inc.'s ($HCA) current $386.09 share price.
- HCA shares traded around $374.95 on Monday, with a market cap of $83.2 billion and a P/E ratio of 12.92.
- Insider transactions include multiple buys by executives in late April and early May 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
TD Cowen has reiterated its buy rating on HCA Healthcare, Inc. (NYSE:HCA), maintaining a price target of $431. This decision was announced on June 22, 2026, with analyst Ryan Langston affirming his positive outlook for the healthcare giant.
TD Cowen vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
HCA Healthcare, Inc. Stock Down 7.6%
Shares of NYSE:HCA traded near $374.95 on Monday. HCA Healthcare boasts a market cap of approximately $83.2 billion. The stock has a P/E ratio of 12.92 and a forward P/E of 11.33. It has a 52-week low of $330.00 and a high of $556.52, with a 50-day moving average of $421.47 and a 200-day moving average of $460.57. The company has a current ratio of 0.83 and a quick ratio of 0.64.
$HCA price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
HCA Healthcare reported revenue of $76.39 billion, reflecting a growth rate of 4.3%. The company's net margin stands at 8.89%, with earnings per share (EPS) of $29.04. The next earnings report is expected on July 24, 2026.
Insider Buying and Selling at HCA Healthcare, Inc.
Recent insider activity includes several transactions on April 28, 2026, where executives such as William Frist, Hugh Johnston, Michael Michelson, and Wayne Joseph Riley purchased shares. Additionally, on May 7, 2026, EVP and CFO Mike Marks both sold and bought 3,336 shares.
Analysts Set New Price Targets
On June 22, 2026, TD Cowen maintained its buy rating for HCA Healthcare with a $431 price target. Earlier, on June 4, 2026, Bernstein maintained a hold rating with a $413 target. In April, several firms including Barclays and RBC Capital also sustained their buy ratings with targets ranging from $496 to $534.
About HCA Healthcare
HCA Healthcare, Inc. operates a comprehensive network of healthcare facilities across the United States. Based in Nashville, Tennessee, and led by CEO Samuel N. Hazen, the company manages a diverse array of hospitals, clinics, and specialized care centers. With about 230,000 employees, HCA provides a wide range of services, from emergency and surgical care to outpatient and therapeutic services.
Bottom Line
TD Cowen's reaffirmation of its buy rating for HCA Healthcare underscores confidence in the company's performance and future prospects. Investors track these ratings closely as they reflect expert analysis and market sentiment. As always, it's important to remember that analyst ratings are just one piece of the investment puzzle.
Get HCA Healthcare, Inc. alerts
New 13F filings, insider trades, and analyst moves on $HCA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.